The small molecule tyrosine kinase inhibitor NVP-BHG712 antagonizes ABCC10-mediated paclitaxel resistance: a preclinical and pharmacokinetic study
Metrics: PDF 1944 views | HTML 2361 views | ?
Rishil J. Kathawala1,8,*, Liuya Wei1,2,*, Nagaraju Anreddy1, Kang Chen3,4,5,6, Atish Patel1, Saeed Alqahtani7, Yun-Kai Zhang1, Yi-Jun Wang1, Kamlesh Sodani1, Amal Kaddoumi7, Charles R. Ashby Jr.1 and Zhe-Sheng Chen1
1 Department of Pharmaceutical Sciences, College of Pharmacy and Health Sciences, St. John’s University, Queens, NY, USA
2 School of Pharmacy and Biological Sciences, Weifang Medical University, Weifang, People’s Republic of China
3 Department of Obstetrics and Gynecology, Wayne State University School of Medicine, Detroit, Michigan, USA
4 Perinatology Research Branch, Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, Maryland, USA
5 Tumor Biology and Microenvironment Program, Barbara Ann Karmanos Cancer Institute, Detroit, Michigan, USA
6 Mucosal Immunology Studies Team, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA
7 Department of Basic Pharmaceutical Sciences, College of Pharmacy, The University of Louisiana, Monroe, LA, USA
8 Current address: Division of Oncology, Stanford University, Stanford, CA, USA
* These authors contributed equally to the work
Zhe-Sheng Chen, email:
Charles R. Ashby Jr., email:
Keywords: NVP-BHG712; ABCC10; ABC transporters; Paclitaxel; Tyrosine kinase inhibitors
Received: September 05, 2014 Accepted: October 28, 2014 Published: October 28, 2014
Paclitaxel exhibits clinical activity against a wide variety of solid tumors. However, resistance to paclitaxel significantly attenuates the response to chemotherapy. The ABC transporter subfamily C member 10 (ABCC10), also known as multi-drug resistance protein 7 (MRP7) efflux transporter, is a major mediator of paclitaxel resistance. Here, we determine the effect of NVP-BHG712, a specific EphB4 receptor inhibitor, on 1) paclitaxel resistance in HEK293 cells transfected with ABCC10, 2) the growth of tumors in athymic nude mice that received NVP-BHG712 and paclitaxel systemically and 3) the pharmacokinetics of paclitaxel in presence or absence of NVP-BHG712. NVP-BHG712 (0.5 μM), in HEK293/ABCC10 cells, significantly enhanced the intracellular accumulation of paclitaxel by inhibiting the efflux activity of ABCC10 without altering the expression level of the ABCC10 protein. Furthermore, NVP-BHG712 (25 mg/kg, p.o., q3d x 6), in combination with paclitaxel (15 mg/kg, i.p., q3d x 6), significantly inhibited the growth of ABCC10-expressing tumors in athymic nude mice. NVP-BHG712 administration significantly increased the levels of paclitaxel in the tumors but not in plasma compared to paclitaxel alone. The combination of NVP-BHG712 and paclitaxel could serve as a novel and useful therapeutic strategy to attenuate paclitaxel resistance mediated by the expression of the ABCC10 transporter.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.